Chinese scientists achieved megabase-scale precise genome editing in eukaryotic cells using programmable chromosome engineering platforms, overcoming limitations of Cre-Lox systems through asymmetric recombinase design and scarless editing techniques. Concurrently, advances in AI-powered molecular tools enable design of binders to intrinsically disordered proteins, historically challenging drug targets. Other highlights include large-scale pedigree-validated genomic variant benchmarks to improve sequencing accuracy, and AI-driven modeling enhancing protein engineering capabilities, signaling a new era in genetic and protein manipulation for research and therapeutic development.